Description
Ramosetron is an inhibitor of 5-HT3 receptors that is currently in clinical trials as a treatment for chemotherapeutic-induced or postoperative nausea and vomiting; it also treats inflammatory bowel syndrome (IBS). Ramosetron exhibits antiemetic and anti-inflammatory activities. Ramosetron inhibits 5-fluorouracil-induced inflammation and mucositis, decreasing expression of IL-6, TNF-α, and IL-1β, decreasing activation of caspases 3 and 8, and preventing apoptosis; this results in decreased body weight loss and disease severity. This compound also allows gastrointestinal transit and inhibits stress-induced abnormal defecation in vivo.